lenalidomide induces ubiquitination degradation ck1a del5q mds 
lenalidomide highly effective treatment myelodysplastic syndrome mds deletion chromosome 5q del5q demonstrate lenalidomide induces ubiquitination casein kinase 1a1 ck1 alpha e3 ubiquitin ligase cul4-rbx1-ddb1-crbn known crl4crbn resulting ck1 alpha degradation ck1 alpha encoded gene within common deleted region del5q mds haploin sufficient expression sensitizes cells lenalidomide therapy providing mechanistic basis therapeutic window lenalidomide del5q mds found mouse cells resistant lenalidomide changing single amino acid mouse crbn corresponding human residue enables lenalidomide-dependent degradation ck1 alpha demonstrate minor side chain modifications thalidomide novel analogue cc- can modulate spectrum substrates targeted crl4crbn findings implications clinical activity lenalidomide related compounds demonstrate therapeutic potential novel modulators e3 ubiquitin ligases 
